SYSTM Wealth Solutions LLC Acquires Shares of 6,004 ICON Public Limited (NASDAQ:ICLR)

SYSTM Wealth Solutions LLC bought a new stake in shares of ICON Public Limited (NASDAQ:ICLR – Get Rating) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 6,004 shares of the medical research company’s stock, valued at approximately $1,166,000.

Other institutional investors also recently made changes to their positions in the company. Laurel Wealth Advisors Inc. grew its holdings in ICON Public by 2.0% in the 1st quarter. Laurel Wealth Advisors Inc. now owns 2,708 shares of the medical research company’s stock worth $658,000 after buying an additional 54 shares in the last quarter. Handelsbanken Fonder AB grew its holdings in ICON Public by 1.2% in the 4th quarter. Handelsbanken Fonder AB now owns 8,330 shares of the medical research company’s stock worth $1,618,000 after buying an additional 100 shares in the last quarter. Financial Management Professionals Inc. boosted its stake in ICON Public by 93.6% during the 4th quarter. Financial Management Professionals Inc. now owns 242 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 117 shares in the last quarter. Tributary Capital Management LLC boosted its stake in ICON Public by 5.0% during the 4th quarter. Tributary Capital Management LLC now owns 2,461 shares of the medical research company’s stock valued at $478,000 after purchasing an additional 118 shares in the last quarter. Finally, Whittier Trust Co. boosted its stake in ICON Public by 11.0% during the 4th quarter. Whittier Trust Co. now owns 1,344 shares of the medical research company’s stock valued at $261,000 after purchasing an additional 133 shares in the last quarter. 92.32% of the stock is owned by institutional investors.

ICON Public Stock Down 0.5 %

Shares of ICLR traded down $1.06 during mid-day trading on Friday, reaching $201.93. The company’s stock had a trading volume of 27,725 shares, compared to its average volume of 575,686. The business has a fifty day moving average of $204.72 and a 200 day moving average of $212.28. The company has a market cap of $16.50 billion, a price-to-earnings ratio of 32.85, a price-to-earnings-growth ratio of 1.21 and a beta of 1.12. ICON Public Limited has a 1 year low of $171.43 and a 1 year high of $249.62. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.50.

ICON Public (NASDAQ:ICLR – Get Rating) last released its earnings results on Wednesday, February 22nd. The medical research company reported $2.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.91 by $0.08. ICON Public had a return on equity of 11.16% and a net margin of 6.52%. The company had revenue of $1.96 billion during the quarter, compared to analyst estimates of $1.95 billion. As a group, analysts forecast that ICON Public Limited will post 11.88 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Guggenheim decreased their price target on ICON Public from $271.00 to $263.00 in a research note on Friday, April 28th. Barclays decreased their price target on ICON Public from $260.00 to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, April 4th. Wells Fargo & Company cut their price objective on ICON Public from $245.00 to $220.00 in a research report on Monday, May 1st. Robert W. Baird cut their price objective on ICON Public from $280.00 to $270.00 in a research report on Monday, May 1st. Finally, Citigroup cut their price objective on ICON Public from $270.00 to $250.00 in a research report on Friday, April 28th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $257.30.

ICON Public Profile

(Get Rating)

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development.